<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131948</url>
  </required_header>
  <id_info>
    <org_study_id>REB 12-5032A</org_study_id>
    <nct_id>NCT02131948</nct_id>
  </id_info>
  <brief_title>Regulation of Endogenous Glucose Production by Brain Insulin Action</brief_title>
  <acronym>Nasal insulin</acronym>
  <official_title>Regulation of Endogenous Glucose Production by Brain Insulin Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that the hormone insulin lowers blood glucose in part by acting directly on&#xD;
      the liver and reducing hepatic glucose production. Animal studies have shown that the hormone&#xD;
      insulin can act on the brain to indirectly lower glucose production by the liver. We aim to&#xD;
      test whether this is true in humans by giving insulin intranasally. It has previously been&#xD;
      shown that a nasal spray can deliver insulin directly to the brain without affecting&#xD;
      circulating insulin concentration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each study participant will be admitted to hospital the evening prior to the study. Following&#xD;
      admission each study participant will be provided with a standardized dinner. At 7am (t=0)&#xD;
      the next day we will begin a primed, constant intravenous infusion d2 glucose (a stable&#xD;
      isotope of glucose, the enrichment of which can be measured by gas chromatography mass&#xD;
      spectrometry, allowing us to calculate endogenous glucose production rates) and continue this&#xD;
      for 8 hours. At the same time (7am) a pancreatic clamp will be started as described above for&#xD;
      8 hours. Blood samples will be analysed with a glucometer for instant blood glucose readings&#xD;
      At 9 am (+120 minutes) intranasal placebo or insulin will be administered. The insulin&#xD;
      (Humalog Lispro 100 IU/ml, Eli Lily, Canada) and placebo (diluent) will be transferred to a&#xD;
      metered nasal device (Pharmasystems, Ontario UPC: 063636 802721, Item 10271) immediately&#xD;
      prior to use. This device dispenses 0.1ml (10 IU) per puff. 4X0.1 ml puffs/vials (2 per&#xD;
      nostril) will be administered at rate of 2 (one in each nostril) every 60 seconds. Blood will&#xD;
      be drawn at t=0, 30, 60, 120 and every 10 minutes thereafter for 6 hours. In order to match&#xD;
      peripheral lispro concentrations between study visits, a small dose of Humalog (lispro)&#xD;
      insulin will be administered intravenously at 9am, during the placebo arm of the study. Based&#xD;
      on the pharmacokinetics of Humalog lispro (personal communication from Eli Lilly), we propose&#xD;
      to administer 0.005 IU/kg over 30 minutes. 20% dextrose will be administered to maintain&#xD;
      euglycemia as necessary. Insulin, glucagon, and glucose isotopic enrichment will be measured.&#xD;
      The enrichment data and glucose infusion will be used to calculate steady state glucose&#xD;
      production.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>8 hours</time_frame>
    <description>Effects of intranasal insulin and placebo on endogenous glucose production will be assessed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Insulin Resistance, Diabetes</condition>
  <arm_group>
    <arm_group_label>Intranasal insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of intranasal insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator to intranasal insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal insulin</intervention_name>
    <description>Intranasal spray</description>
    <arm_group_label>Intranasal insulin</arm_group_label>
    <other_name>Humalog lispro 40 IU intranasally</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal placebo</intervention_name>
    <description>Intranasal spray</description>
    <arm_group_label>Intranasal placebo</arm_group_label>
    <other_name>Diluent intranasally</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, aged 18 to 60 years&#xD;
&#xD;
          2. Body mass index 20-27.&#xD;
&#xD;
          3. Hemoglobin in the normal range.&#xD;
&#xD;
          4. Normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test&#xD;
&#xD;
          5. Women of reproductive age should be on contraception (oral contraceptive pill or&#xD;
             intra-uterine device/coil) for at least 2 months prior to and after the study.&#xD;
&#xD;
        Volunteers who have taken part in the study with the previously approved protocol will be&#xD;
        eligible to participate in the amended study, if they provide their informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Study participant with a history of hepatitis/hepatic disease that has been active within&#xD;
        the previous two years.&#xD;
&#xD;
        2. Any current or previous history of biliary disease (including gall stones, biliary&#xD;
        atresia and cholecystitis) or pancreatitis.&#xD;
&#xD;
        3. Any current or previous history of endocrine disease, dyslipidemia or malignancy 4. Any&#xD;
        significant active (over the past 12 months) disease of the gastrointestinal, pulmonary,&#xD;
        neurological, renal (Cr &gt; 1.5 mg/dL) genitourinary, hematological systems, or has severe&#xD;
        uncontrolled treated or untreated hyper/ hypotension (sitting diastolic BP &gt; 100 or&#xD;
        systolic &gt; 180 or systolic BP&lt;100) or proliferative retinopathy 5. Use of immunosuppressive&#xD;
        agents at any time during the study 6. Allergy to any study medication 7. Pregnancy or&#xD;
        breastfeeding 8. Heavy smoker 9. Prior nasoduodenal tube insertion under fluoroscopic&#xD;
        guidance. 10. Fasting blood glucose &gt; 6.0 mmol/l or known diabetes. 11. Any history of a MI&#xD;
        or clinically significant, active, cardiovascular history including a history of&#xD;
        arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.&#xD;
&#xD;
        12. Any nasal pathology likely to affect absorption of insulin or insertion of nasoduodenal&#xD;
        tube.&#xD;
&#xD;
        13. Any laboratory values: AST &gt; 2x ULN; ALT &gt; 2x ULN TSH &gt; 6 mU/l 14. Current addiction to&#xD;
        alcohol or substances of abuse as determined by the investigator.&#xD;
&#xD;
        15. Mental incapacity, unwillingness or language barrier precluding adequate understanding&#xD;
        or cooperation 16. Taking any regular prescription or non-prescription medications at the&#xD;
        time of the study. Occasional use of medications such as acetoaminophen or Tylenol 1 or any&#xD;
        use of natural health products may be permitted at the discretion of the investigator.&#xD;
&#xD;
        17. Will not donate blood three months prior to and three months post study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tornto General Hospital, UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 2, 2014</study_first_submitted>
  <study_first_submitted_qc>May 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Brain insulin action</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

